HIGH TUMOR STROMA PROPORTION IS A WORSE PROGNOSTIC FACTOR IN COLORECTAL CANCER
|
|
- Maximilian Stanley
- 5 years ago
- Views:
Transcription
1 Acta Clin Croat 2017; 56:73-79 Original Scientific Paper doi: /acc HIGH TUMOR STROMA PROPORTION IS A WORSE PROGNOSTIC FACTOR IN COLORECTAL CANCER Josipa Flam 1,2, Damir Gugić 1,2, Mirta Benšić 3, Snježana Tomić 4 and Jasmina Rajc 2,5 1 Department of Oncology, Osijek University Hospital Center; 2 School of Medicine, 3 Department of Mathematics, Josip Juraj Strossmayer University, Osijek; 4 Clinical Department of Pathology, Split University Hospital Center, Split; 5 Clinical Department of Pathology, Osijek University Hospital Center, Osijek, Croatia SUMMARY High stroma proportion appears to be a very important prognostic factor in esophageal and breast cancer. Previous researches have shown that it might have a similar effect on colorectal cancer. The aim of this study was to determine whether tumor stroma proportion influenced patient survival. This retrospective study included 236 patients with colorectal cancer having undergone surgery in 2006 and 2007 at Osijek University Hospital Center. Location with the highest stroma proportion at the site of deepest tumor invasion was determined. Patients were divided into the groups with high stroma proportion (>50%) and low stroma proportion ( 50%). Stroma proportion showed a statistically significant correlation with tumor stage. Kaplan-Meier survival curves yielded a statistically significant difference in patient overall survival (Cox ph model p=0.016) and progressionfree survival (Cox ph model, p=0.0188) according to stroma proportion. Study results showed a statistically significantly shorter overall survival and progression-free survival in patients with high stroma proportion. Key words: Colorectal neoplasms; Stromal cells; Survival; Disease-free survival; Disease progression; Prognosis Introduction Colorectal cancer is a huge health issue. Unfortunately, the incidence and mortality of colorectal cancer have been growing in Croatia as opposed to developed countries 1,2. Postoperative patient treatment poses a special kind of problem 3. Patients with disease stage I are not indicated any additional therapy after the surgery 4. Patients with disease stage III are indicated additional chemotherapy after the surgery 5. Patients with disease stage II present a special problem; about 25% of these patients have disease recurrence within 5 Correspondence to: Josipa Flam, MD, Clinical Department of Oncology, Osijek University Hospital Center, J. Huttlera 4, HR Osijek, Croatia jflam@mefos.hr Received December 14, 2016, accepted January 16, 2017 years 6. The influence of additional chemotherapy on patients with disease stage II has been the basis for several clinical trials. Results of a meta-analysis of 5 trials have shown patients with disease stage III to benefit most from additional chemotherapy 6-8. However, new results of 12 controlled clinical studies from 1988 to 2010 have shown significant benefit of additional chemotherapy in patients with disease stage II 9. On the other hand, the Quasar Collaborative Group study 6 has shown little benefit of chemotherapy compared to no chemotherapy in patients with disease stage II. The benefit was about 3.6%. This percentage is below the accepted level of 5% and therefore chemotherapy for the entire stage II group is not advised. Numerous studies have shown which parameters mean worse prognosis for patients with colorectal cancer. These parameters include evaluation of less than Acta Clin Croat, Vol. 56, No. 1,
2 Fig. 1. Determination of stroma proportion using computer Adobe Photoshop CS2 when tumor is covering whole photo. Fig. 2. Determination of stroma proportion using computer program Adobe Photoshop CS2 when tumor is not covering whole photo. 12 lymph nodes 11, lymphovascular or perineural invasion, poor tumor differentiation, younger age, close resection lines, and perforation during or after surgery 4,12. Based on these parameters, it is decided whether patients will receive chemotherapy. In practice, we often encounter patients that have good prognostic factors but their metastatic disease develops very soon. Patients with a small primary tumor sometimes have a metastatic disease at the beginning. A simple concept according to which tumor progression depends only on the intrinsic ability of tumor cells has been ever more widely rejected in the last couple of years. This points to the fact that tumor progression is the result of interaction between tumor and stroma cells, as well as the surrounding stroma cells 13,14. The researches known so far have confirmed that tumor stroma influences tumor growth, angiogenesis and dissemination. It is believed that stroma induces tumorigenesis by various mechanisms such as remodeling of extracellular matrix, suppression of immune response and motility, as well as aggressiveness of cancer cells It has been evident that stroma has a prognostic value in esophageal cancer 18,19 and breast cancer 20, especially triple negative breast cancer 21,22. Using simple modified methodology, we tried to determine the impact of stroma proportion on progression-free survival and overall survival. We also tried to determine the association of tumor stroma 74 Acta Clin Croat, Vol. 56, No. 1, 2017
3 with previously known histopathologic features of the tumor. We tried to use simple, innovative methodology to quantifiy stroma proportion. Patients and Methods Our study included patients having undergone colorectal cancer surgery in 2006 and 2007 at Clinical Department of Surgery, and then treated or monitored at Clinical Department of Oncology, Osijek University Hospital Center. From analysis were excluded patients that had only colonoscopy and no surgery, and patients that died within a month after surgery (perioperative mortality). Patients that had received neoadjuvant oncologic therapy (neoadjuvant chemoradiotherapy for rectal cancer), patients with a history of malignant tumor and those with two synchronous colon cancers were not included in analysis. Considering patients having undergone surgery at Clinical Department of Surgery but not treated at Clinical Department of Oncology, Osijek University Hospital Center, only data that could be read from histopathologic findings kept at Department of Pathology, Osijek University Hospital Center were included in analysis. Department of Pathology provided data on histopathologic features of the tumor (tumor size, tumor stage, number of lymph nodes removed, number of lymph nodes with tumor cells, tumor grade of differentiation, presence of lymphovascular or perineural invasion, tumor distance from resecting edge, and whether the patient underwent surgery for metastases). Medical history of patients provided by Clinical Department of Oncology included data on patient sex and age, date of surgery, type of surgery, metastases and their locations, and adjuvant treatment of patients. We also received information on the date of disease progression, date of the last examination, and date of death for the patients that died. Our pathologist identified the area of deepest tumor invasion with highest stroma proportion. Then he took a photo of this area at 20X magnification using Bx41 Olympus microscope with Olympus C-4040 digital camera. Using a computer program Adobe Photoshop CS2, we manually determined stroma area using green color (Fig. 1). Then we calculated the proportion of stroma based on the number of pixels (the number of green pixels/total image pixels (241968)). On most photos, tumor covered the whole photo, but Table 1. Demographic and tumor characteristics Gender Tumor site T stage N stage M stage TNM stage Lymphovascular and perineural invasion Tumor differentiation Tumor stroma proportion on some photos it was not possible due to the size of the tumor (Fig. 2). In this case, the number of yellow colored points was subtracted from the whole number of picture pixels. The areas of necrosis were yellow colored, while mucus that was part of the tumor was not yellow but remained colorless. Tumor stroma proportion was calculated afterwards. The cut-off point between high and low stroma proportion was set at 50%. Statistics Male Female Left Right T1 T2 T3 T4 N0 N1 N2 M0 M1 I II III IV Yes No Good Moderate Poor Low (<50%) High (>50%) n (%) 130 (55.08) 106 (44.92) 146 (71.22) 59 (28.78) 1 (1.28) 29 (12.34) 185 (78.72) 18 (7.66) 72 (33.96) 56 (26.42) 84 (39.62) 163 (77.62) 47 (22.38) 22 (10.43) 56 (26.54) 87 (41.23) 46 (21.80) 59 (25.11) 176 (74.89) 103 (50.24) 90 (43.909) 12 (5.86) 131 (55.51) 105 (44.49) Categorical data were presented as absolute and relative frequencies. Numerical data were presented as mean and standard deviation and, if necessary, with median and quartiles and other standard measures of descriptive statistics. Analysis of variance was used to determine relationship between stroma proportion and other histopathologic characteristics. Overall survival and progression-free survival were estimated by Kaplan-Meier survival curves. Differences in overall survival and progression-free survival were tested us- Acta Clin Croat, Vol. 56, No. 1,
4 Table 2. Relationship between overall survival and tumor characteristics Median OS/days CI (95%) p value Localization Right NA 2380-NA Left T stage T2 NA NA-NA T T NA N stage N0 NA 2397-NA <0.001 N NA N M stage M NA <0.001 M TNM stage I NA NA-NA <0.001 II NA III NA IV Tumor differentiation Lymphovascular and perineural invasion ing the Cox ph model, likelihood ratio test, and logrank test. The level of significance was set at On statistical analysis, was used STATISTICA64 (version 11, StatSoft.Inc., Tulsa, OK, USA) statistical program and software package R, library OIsurv for survival analysis 23. Results NA NA NA Yes NA No NA NA = not applicable; OS = overall survival; log-rank test The analysis included 236 patients with all tumor stages, mean age (standard deviation (SD) 11.46) years. They all had undergone surgery at Cinical Department of Surgery, Osijek University Hospital Center, and 206 of them were then treated and followed up at Clinical Department of Oncology, Osijek University Hospital Center. Demographic characteristics of patients and histopathologic characteristics of tumors are shown in Table 1. Table 3. Relationship between progression-free survival and tumor characteristics Median CI (95%) PFS/days p value Localization Right NA 896-NA Left T stage T2 NA 2553-NA T T NA N stage N0 NA NA-NA <0.001 N NA N M stage M NA <0.001 M TNM stage I NA <0.001 II NA 1710-NA III NA IV Tumor NA differentiation NA Lymphovascular and perineural invasion Yes No NA NA = not applicable; PFS = progression-free survival; log rank test We analyzed correlation between tumor stroma, pathologic characteristics of tumor and survival. Stroma proportion was determined in all study patients. The mean value of tumor stroma was 44.23% (SD 12.10%). Analysis of variance confirmed a statistically significant difference in stroma proportion due to tumor T stage (p=0.002) and N stage (p=0.038). Relationship of the median overall survival and histopathologic characteristics of tumor is presented in Table 2. There was no statistically significant difference in overall survival according to tumor localization, tumor differentiation, and perineural and lymphovascular invasion. Relationship between progression-free survival and tumor characteristics is presented in Table 3. There was a statistically significant difference in progression-free survival among all characteristics except for tumor differentiation. The Cox proportional hazards methodology of modeling with a single predictor was used to analyze 76 Acta Clin Croat, Vol. 56, No. 1, 2017
5 Fig. 3. Kaplan-Meier curves of overall survival and tumor stroma proportion. Fig. 4. Kaplan-Meier curves of progression-free survival and tumor stroma proportion. correlation between stroma proportion and patient survival. The likelihood ratio test revealed a statistically significant role of tumor stroma proportion in the models of overall survival (p=0.016) and progressionfree survival (p=0.019). The Kaplan-Meier survival curves of overall survival and tumor stroma proportion are shown in Figure 3, and Kaplan-Meier survival curves of progression-free survival and tumor stroma proportion in Figure 4. Discussion The parameters associated with worse prognosis in patients with colorectal cancer include evaluation of less than 12 lymph nodes 10, lymphovascular or perineural invasion, poor tumor differentiation, younger age, close resection lines, and perforation during or after surgery 3,11. These parameters are not good enough to predict outcome in patients with colorectal cancer. We need more and better parameters in clinical practice. In recent research, some new parameters have emerged that may have a prognostic role in colorectal cancer, one of them being the amount of stroma, which was first demonstrated as a prognostic factor in breast and esophageal cancer The role of stroma proportion, or tumor cell proportion in the prognosis of colorectal cancer has been reported in four papers so far; they have demonstrated the proportion of stroma to be a significant prognostic factor in colorectal cancer and the higher proportion of tumor stroma to be associated with better patient prognosis 24,25,28,29. In 2007, Mesker et al. showed the carcinoma-stroma ratio to be an independent factor for survival as compared with lymph node status and tumor stage 24. In 2010, West et al. proved the smaller cancer cell proportion to be an independent prognostic factor for survival in colorectal cancer 25. In 2012, the VICTOR trial was started 26,27. The authors planned to include 7000 pa- Acta Clin Croat, Vol. 56, No. 1,
6 tients. The purpose of this study was to test whether the COX-2 inhibitor rofecoxib could reduce recurrence and improve survival when administered in the adjuvant setting of colorectal cancer stage II and III. Since cardiotoxicity of refecoxib had been established, the trial was stopped. Results of this huge trial including over 700 patients have confirmed previous results that stroma is an independent prognostic factor in colorectal cancer stage II and III 28, which was confirmed in the study conducted by Park et al. in Our trial confirmed difference in overall survival and progression-free survival. This difference was statistically significant, which is consistent with previous studies. Previous trials have shown strong heterogeneity in tumor cells within the tumor. The stroma proportion is not the same throughout the tumor. In breast cancer, some studies have shown that tumors with a high proportion of tumor cells at the periphery of the tumor have better prognosis 30, while others report opposite findings when looking at the entire tumor 31. In previous trials, researchers used subjective methodology where two independent pathologists tried to estimate stroma proportion 27,28, while Mesker et al. used a software that is not available in every hospital 24. In our trial, we tried to quantify stroma proportion using a simple, widely accessible methodology. Using this methodology, it is simple to determine stroma proportion. According to previous trials 24,25,28,29 and the fact that it is impossible to determine stroma proportion in the whole tumor, we believe that the area with the largest stroma proportion at the site with deepest tumor penetration is adequate to analyze and set the stroma proportion as a prognostic factor for colorectal cancer. In conclusion, our study showed the importance of tumor stroma proportion in determining outcome in patients with colorectal cancer. As it is simple to determine, it could be included as a prognostic parameter in the routine histopathologic reports. References 1. Hrvatski zavod za javno zdravstvo. Registar za rak Republike Hrvatske. Incidencija raka u Hrvatskoj 2013., Bilten 38, Zagreb, (in Croatian) 2. Tripković I, Strnad M, Polić Vižintin M, Mulić R, Tripković I. Colorectal cancer in Split-Dalmatia County. Acta Clin Croat Sep;48(4): Wishner JD, Baker JW Jr, Hoffman GC, Hubbard GW 2 nd, Gould RJ, et al. Laparoscopic-assisted colectomy. The learning curve. Surg Endosc. 1995;9(11): National Comprehensive Cancer Network. Guideliness for treating cancer by site, version Des Guetz G, Uzzan B, Morere JF, Perret G, Nicolas P. Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancer. Cochrane Database Syst Rev Jan 20;(1):CD doi: / CD pub2 6. Gray R, Barnewell J, McConkey C, et al. Adjuvant therapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007;370: doi: /S (07) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet Apr 15;345 (8955): Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) investigators. J Clin Oncol May;17(5): Hanna NN, Onukwugha E, Choti MA, et al. Comparative analysis of various prognostic nodal factors, adjuvant chemotherapy and survival among stage III colon cancer patients over 65 years: an analysis using surveillance, epidemiology and end results (SEER) Medicare data. Colorectal Dis Jan; 14(1): doi: /j x 10. Wu X, Zhang J, He X, Wang C, Lian L, et al. Postoperative adjuvant chemotherapy for stage II colorectal cancer: a systematic review of 12 randomized controlled trials. J Gastrointest Surg Mar;16(3): doi: /s Epub 2011 Dec Nedrebø BS, Søreide K, Nesbakken A, et al. Risk factors associated with poor lymph node harvest after colon cancer surgery in a national cohort. Colorectal Dis. 2013;15(6):e doi: /codi Lykke J, Rojkjaer O, Jess P; Danish Colorectal Cancer Group. The relation between lymph node status and survival in stage I-III colon cancer: results from a prospective nationwide cohort study. Colorectal Dis May;15(5): doi: / codi Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7): doi: /carcin/bgp127. Epub 2009 May Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5): doi: /j.cell Kim JB, Stein R, O Hare MJ. Tumour-stromal interactions in breast cancer: the role of stroma in tumourigenesis. Tumor Biol. 2005;26(4): doi: / Hu M, Polyak K. Microenvironmental regulation of cancer development. Curr Opin Genet. 2008;18(1): doi: /j. gde Epub 2008 Feb Acta Clin Croat, Vol. 56, No. 1, 2017
7 17. Cirri P, Chiarugi P. Cancer-associated fibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer Metastasis Rev. 2012;31(1-2): doi: /s x 18. Wang K, Ma W, Wang J, Yu L, Zhang X, et al. Tumor-stroma ratio is an independent predictor for survival in esophageal squamous cell carcinoma. J Thorac Oncol. 2012;7(9): doi: /JTO.0b013e318260dfe8 19. Courrech Staal EF, Wouters MW, van Sandick JW, Takkenberg MM, Smit VT, et al. The stromal part of adenocarcinomas of the oesophagus: does it conceal targets for therapy? Eur J Cancer. 2010;46(4): doi: /j.ejca Epub 2010 Jan Gujam FA, Edwards J, Mohammed MA, Going JJ, McMillan DC. The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer. Br J Cancer. 2014;111: doi: /bjc Epub 2014 May de Kruijf EM, van Nes JG, Van de Velde CJ, Putter H, Smit VT, et al. Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triplenegative carcinoma patients. Breast Cancer Res Treat. 2011; 125(3): doi: /s Epub 2010 Apr Moorman AM, Vink R, Heijmans HJ, van der Palen J, Kouwenhoven EA. The prognostic value of tumour-stroma ratio in triple-negative breast cancer. Eur J Surg Oncol. 2012;38(4): doi: /j.ejso Epub 2012 Jan Diez DM. Package OIsurv. packages/oisurv/oisurv.pdf ( ) 24. Mesker WE, Junggeburt JM, Szuhai K, de Heer P, Morreau H, Tanke HJ, Tollenaar RA. The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell Oncol. 2007;29(5): West NP, Dattani M, McShane P, Hutchins G, Grabsch J, et al. The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients. Br J Cancer. 2010;102 (10): doi: /sj.bjc Epub 2010 Apr Midgley RS, McConkey CC, Johnstone EC, et al. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of VICTOR trial. J Clin Oncol. 2010;28: doi: /JCO Epub 2010 Sep Pendlebury S, Duchesne F, Reed KA, et al. A trial adjuvant therapy in colorectal cancer: the VICTOR trial. Clin Colorectal Cancer. 2003;3: doi: /CCC.2003.n Huijbers A, Tollenaar RA, Pelt GW, Zeestraten EC, Dutton S, et al. The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Ann Oncol. 2013;24(1): doi: / annonc/mds246. Epub 2012 Aug Park J, Richards C, McMillan D, Horgan P, Roxburgh C. The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. Ann Oncol. 2014;25(3): doi: /annonc/mdt593. Epub 2014 Jan Baak JP, Van Dop H, Kurver PH, Hermans J. The value of morphometry to classic prognosticators in breast cancer. Cancer Jul 15;56(2): Tanaka K, Yamamoto D, Yamada M, Okugawa H. Influence of cellularity in human breast carcinoma. Breast Aug;13 (4): doi: /j.breast Sažetak UDIO TURMOSKE STROME KAO LOŠ PROGNOSTIČKI ČIMBENIK KOD KARCINOMA DEBELOG CRIJEVA J. Flam, D. Gugić, M. Benšić, S. Tomić i J. Rajc Dokazano je da je visok udio strome značajan prognostički čimbenik kod karcinoma jednjaka i karcinoma dojke. Prethodna istraživanja su pokazala da bi isti utjecaj stroma mogla imati i kod kolorektalnog karcinoma. Cilj istraživanja je bio utvrditi je li udio tumorske strome povezan s preživljenjem bolesnika s kolorektalnim karcinomom. Provedeno je retrospektivno istraživanje u 236 bolesnika koji su operirani na Klinici za kirurgiju Kliničkoga bolničkog centra Osijek. Određeno je područje s najvećim udjelom strome u području najdubljeg prodora tumora. Bolesnici su podijeljeni u dvije skupine: onu s visokim udjelom strome (>50%) i onu s niskim udjelom strome ( 50%). Udio tumorske strome bio je statistički značajno povezan sa stadijem tumora. Kaplan-Meierova analiza je pokazala statistički značajnu razliku u ukupnom preživljenju (Cox ph model p=0,016) i preživljenju do progresije (Cox ph model, p=0,0188) bolesnika u odnosu na udio strome. Rezultati su pokazali statistički značajno kraće ukupno preživljenje i preživljenje do progresije bolesti kod bolesnika s visokim udjelom strome. Ključne riječi: Kolorektalni tumori; Stromalne stanice; Preživljavanje; Bolest, napredovanje; Preživljavanje bez znakova bolesti; Prognoza Acta Clin Croat, Vol. 56, No. 1,
Disclosures. Outline. What IS tumor budding?? Tumor Budding in Colorectal Carcinoma: What, Why, and How. I have nothing to disclose
Tumor Budding in Colorectal Carcinoma: What, Why, and How Disclosures I have nothing to disclose Soo-Jin Cho, MD, PhD Assistant Professor UCSF Dept of Pathology Current Issues in Anatomic Pathology 2017
More informationLymph node ratio as a prognostic factor in stage III colon cancer
Lymph node ratio as a prognostic factor in stage III colon cancer Emad Sadaka, Alaa Maria and Mohamed El-Shebiney. Clinical Oncology department, Faculty of Medicine, Tanta University, Egypt alaamaria1@hotmail.com
More informationSurgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database
Surgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database Hadi Khan, MD 1, Adam J. Olszewski, MD 2 and Ponnandai S. Somasundar, MD 1 1 Department
More informationMismatch repair status, inflammation and outcome in patients with primary operable colorectal cancer
Mismatch repair status, inflammation and outcome in patients with primary operable colorectal cancer Park JH, Powell AG, Roxburgh CSD, Richards CH, Horgan PG, McMillan DC, Edwards J James Park Clinical
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationLower lymph node yield following neoadjuvant therapy for rectal cancer has no clinical significance
Original Article Lower lymph node yield following neoadjuvant therapy for rectal cancer has no clinical significance Dedrick Kok Hong Chan 1,2, Ker-Kan Tan 1,2 1 Division of Colorectal Surgery, University
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationPATHOLOGIC FACTORS PROGNOSTIC OF SURVIVAL IN PATIENTS WITH GI TRACT AND PANCREATIC CARCINOMA TREATED WITH NEOADJUVANT THERAPY
PATHOLOGIC FACTORS PROGNOSTIC OF SURVIVAL IN PATIENTS WITH GI TRACT AND PANCREATIC CARCINOMA TREATED WITH NEOADJUVANT THERAPY Jeannelyn S. Estrella, MD Department of Pathology The UT MD Anderson Cancer
More informationSurgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study
Original article Annals of Gastroenterology (2013) 26, 346-352 Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study Subhankar Chakraborty
More informationWHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER?
CANCER STAGING TNM and prognosis in CRC WHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER? Alessandro Lugli, MD Institute of Pathology University of Bern Switzerland Maastricht, June 19
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationLog odds of positive lymph nodes is a novel prognostic indicator for advanced ESCC after surgical resection
Original Article Log odds of positive lymph nodes is a novel prognostic indicator for advanced ESCC after surgical resection Mingjian Yang 1,2, Hongdian Zhang 1,2, Zhao Ma 1,2, Lei Gong 1,2, Chuangui Chen
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationReconsideration of the optimal minimum lymph node count for young colon cancer patients: a population-based study
Guan et al. BMC Cancer (2018) 18:623 https://doi.org/10.1186/s12885-018-4428-0 RESEARCH ARTICLE Reconsideration of the optimal minimum lymph node count for young colon cancer patients: a population-based
More informationThe effect of delayed adjuvant chemotherapy on relapse of triplenegative
Original Article The effect of delayed adjuvant chemotherapy on relapse of triplenegative breast cancer Shuang Li 1#, Ding Ma 2#, Hao-Hong Shi 3#, Ke-Da Yu 2, Qiang Zhang 1 1 Department of Breast Surgery,
More informationImprovement of the multimodality treatment of oesophageal cancer Courrech Staal, E.F.W.
UvA-DARE (Digital Academic Repository) Improvement of the multimodality treatment of oesophageal cancer Courrech Staal, E.F.W. Link to publication Citation for published version (APA): Courrech Staal,
More informationCharacteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation
More informationEmbolotherapy for Cholangiocarcinoma: 2016 Update
Embolotherapy for Cholangiocarcinoma: 2016 Update Igor Lobko,MD Chief, Division Vascular and Interventional Radiology Long Island Jewish Medical Center GEST 2016 Igor Lobko, M.D. No relevant financial
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/55957 holds various files of this Leiden University dissertation Author: Dekker T.J.A. Title: Optimizing breast cancer survival models based on conventional
More informationHigh risk stage II colon cancer
High risk stage II colon cancer Joel Gingerich, MD, FRCPC Assistant Professor Medical Oncologist University of Manitoba CancerCare Manitoba Disclaimer No conflict of interests 16 October 2010 Overview
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/38705 holds various files of this Leiden University dissertation. Author: Gijn, Willem van Title: Rectal cancer : developments in multidisciplinary treatment,
More informationDifferential lymph node retrieval in rectal cancer: associated factors and effect on survival
Original Article Differential lymph node retrieval in rectal cancer: associated factors and effect on survival Cedrek McFadden 1, Brian McKinley 1, Brian Greenwell 2, Kaylee Knuckolls 1, Patrick Culumovic
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationAll India Institute of Medical Sciences, New Delhi, INDIA. Department of Pediatric Surgery, Medical Oncology, and Radiology
All India Institute of Medical Sciences, New Delhi, INDIA Department of Pediatric Surgery, Medical Oncology, and Radiology Clear cell sarcoma of the kidney- rare renal neoplasm second most common renal
More informationGlasgow Prognostic Score (GPS) Can Be a Useful Indicator to Determine Prognosis of Patients With Colorectal Carcinoma
Int Surg 2014;99:512 517 DOI: 10.9738/INTSURG-D-13-00118.1 Glasgow Prognostic Score (GPS) Can Be a Useful Indicator to Determine Prognosis of Patients With Colorectal Carcinoma Tadahiro Nozoe, Rumi Matono,
More informationResearch Article Survival Benefit of Adjuvant Radiation Therapy for Gastric Cancer following Gastrectomy and Extended Lymphadenectomy
International Surgical Oncology Volume 2012, Article ID 307670, 7 pages doi:10.1155/2012/307670 Research Article Survival Benefit of Adjuvant Radiation Therapy for Gastric Cancer following Gastrectomy
More informationNatural History and Treatment Trends in Hepatocellular Carcinoma Subtypes: Insights From a National Cancer Registry
2015;112:872 876 Natural History and Treatment Trends in Hepatocellular Carcinoma Subtypes: Insights From a National Cancer Registry PETER L. JERNIGAN, MD, KOFFI WIMA, MS, DENNIS J. HANSEMAN, PhD, RICHARD
More informationComparison of lymph node number and prognosis in gastric cancer patients with perigastric lymph nodes retrieved by surgeons and pathologists
Original Article Comparison of lymph node number and prognosis in gastric cancer patients with perigastric lymph nodes retrieved by surgeons and pathologists Lixin Jiang, Zengwu Yao, Yifei Zhang, Jinchen
More informationJi-Feng Feng 1,2*, Ying Huang 3 and Qi-Xun Chen 1,2 WORLD JOURNAL OF SURGICAL ONCOLOGY
Feng et al. World Journal of Surgical Oncology 2014, 12:58 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Preoperative platelet lymphocyte ratio (PLR) is superior to neutrophil lymphocyte ratio
More informationThe tumor-stromal ratio as a strong prognosticator for advanced gastric cancer patients: proposal of a new TSNM staging system
J Gastroenterol (2018) 53:606 617 https://doi.org/10.1007/s00535-017-1379-1 ORIGINAL ARTICLE ALIMENTARY TRACT The tumor-stromal ratio as a strong prognosticator for advanced gastric cancer patients: proposal
More informationPoor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas
10 The Open Otorhinolaryngology Journal, 2011, 5, 10-14 Open Access Poor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas Kevin C. Huoh and Steven J. Wang * Head and Neck Surgery and Oncology,
More informationIn 1989, Deslauriers et al. 1 described intrapulmonary metastasis
ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,
More informationThe Egyptian Journal of Hospital Medicine (July 2018) Vol. 72 (9), Page
The Egyptian Journal of Hospital Medicine (July 2018) Vol. 72 (9), Page 5298-5303 Prognostic Value of Platelet to Lymphocyte Ratio in Patients with Non-Small Cell Lung Cancer Mohammad Sabry Elkady, Ghada
More informationThe Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer
Original Article The Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer Chen Qiu, MD,* Wei Dong, MD,* Benhua Su, MBBS, Qi Liu, MD,* and Jiajun Du, PhD Introduction:
More informationRole of Primary Resection for Patients with Oligometastatic Disease
GBCC 2018, April 6, Songdo ConvensiA, Incheon, Korea Panel Discussion 4, How Can We Better Treat Patients with Metastatic Disease? Role of Primary Resection for Patients with Oligometastatic Disease Tadahiko
More informationDesmoplastic Melanoma: Surgical Management and Adjuvant Therapy
Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Dale Han, MD Assistant Professor Department of Surgery Section of Surgical Oncology No disclosures Background Desmoplastic melanoma (DM)
More informationPhysician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer
Physician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer Gabriela M. Vargas, MD Kristin M. Sheffield, PhD, Abhishek Parmar, MD, Yimei Han, MS, Kimberly M. Brown,
More informationAnalysis of the outcome of young age tongue squamous cell carcinoma
Jeon et al. Maxillofacial Plastic and Reconstructive Surgery (2017) 39:41 DOI 10.1186/s40902-017-0139-8 Maxillofacial Plastic and Reconstructive Surgery RESEARCH Open Access Analysis of the outcome of
More informationWhen to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationPMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center
PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic
More informationThyroid Cancer: When to Treat? MEGAN R. HAYMART, MD
Thyroid Cancer: When to Treat? MEGAN R. HAYMART, MD ASSOCIATE PROFESSOR OF MEDICINE UNIVERSITY OF MICHIGAN MICHIGAN AACE 2018 ANNUAL MEETING Thyroid Cancer: When Not to Treat? FOCUS WILL BE ON LOW-RISK
More informationLocoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
More informationDeposited on: 4 November 2009
Roxburgh, C.S.D. and Crozier, J.E.M. and Maxwell, F. and Foulis, A.K. and Brown, J. and McKee, R.F. and Anderson, J.H. and Horgan, P.G. and McMillan, D.C. (2009) Comparison of tumour-based (Petersen Index)
More informationControversies in Breast Pathology ELENA PROVENZANO ADDENBROOKES HOSPITAL, CAMBRIDGE
Controversies in Breast Pathology ELENA PROVENZANO ADDENBROOKES HOSPITAL, CAMBRIDGE Neoadjuvant Chemotherapy Indications: Management of locally advanced invasive breast cancers including inflammatory breast
More informationADJUVANT CHEMOTHERAPY...
Colorectal Pathway Board: Non-Surgical Oncology Guidelines October 2015 Organization» Table of Contents ADJUVANT CHEMOTHERAPY... 2 DUKES C/ TNM STAGE 3... 2 DUKES B/ TNM STAGE 2... 3 LOCALLY ADVANCED
More informationPrognostic factors in curatively resected pathological stage I lung adenocarcinoma
Original Article Prognostic factors in curatively resected pathological stage I lung adenocarcinoma Yikun Yang 1, Yousheng Mao 1, Lin Yang 2, Jie He 1, Shugeng Gao 1, Juwei Mu 1, Qi Xue 1, Dali Wang 1,
More informationModified primary tumour/vessel tumour/nodal tumour classification for patients with invasive ductal carcinoma of the breast
British Journal of Cancer (2011) 105, 698 708 All rights reserved 0007 0920/11 www.bjcancer.com Modified primary tumour/vessel tumour/nodal tumour classification for patients with invasive ductal carcinoma
More informationRESEARCH ARTICLE. Factors Affecting Survival in Patients with Colorectal Cancer in Shiraz, Iran
DOI:http://dx.doi.org/10.7314/APJCP.2016.17.1.159 RESEARCH ARTICLE Factors Affecting Survival in Patients with Colorectal Cancer in Shiraz, Iran Mohammad Zare-Bandamiri 1, Narges Khanjani 2 *, Yunes Jahani
More informationA systemic review and meta-analysis for prognostic values of pretreatment lymphocyte-to-monocyte ratio on gastric cancer
831094EJI0010.1177/2058739219831094European Journal of InflammationLi et al. letter2019 Letter to the Editor A systemic review and meta-analysis for prognostic values of pretreatment lymphocyte-to-monocyte
More informationHow much colon should be resected?
Colon Cancer Surgical Standard of Care and Operative Techniques Madhulika G. Varma MD Professor and Chief Section of Colorectal Surgery University of California, San Francisco How much colon should be
More informationThe role of hepatic artery lymph node in pancreatic adenocarcinoma: prognostic factor or a selection criterion for surgery
DOI:10.1111/hpb.12306 HPB ORIGINAL ARTICLE The role of hepatic artery lymph node in pancreatic adenocarcinoma: prognostic factor or a selection criterion for surgery Prejesh Philips, Erik Dunki-Jacobs,
More informationThe Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC)
The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC) Disclosure None Background Torino, Italy LCNC Rare tumor (2% to 3% all resected primary lung cancers) Preoperative
More informationUpdates on the Conflict of Postoperative Radiotherapy Impact on Survival of Young Women with Cancer Breast: A Retrospective Cohort Study
International Journal of Medical Research & Health Sciences Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(7): 14-18 I J M R
More informationCirculating Tumor Cells in non- Metastatic Triple Negative Breast Cancer
Circulating Tumor Cells in non- Metastatic Triple Negative Breast Cancer Carolyn Hall, Ph.D. Department of Surgical Oncology The University of Texas MD Anderson Cancer Center Triple Negative Breast Cancer
More informationPatient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival
MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationOriginal Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical outcome
Int J Clin Exp Pathol 2017;10(2):2030-2035 www.ijcep.com /ISSN:1936-2625/IJCEP0009456 Original Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical
More informationDoes Anesthesia influence Cancer recurrence? Dr Ian McConachie FRCA FRCPC London, ON, Canada
Does Anesthesia influence Cancer recurrence? Dr Ian McConachie FRCA FRCPC London, ON, Canada Why did my cancer come back? Inadequate resection Micro metastases Lymph spread Tumour biology Immune system
More informationFinancial Disclosure. Learning Objectives. Review and Impact of the NCDB PUF. Moderator: Sandra Wong, MD, MS, FACS, FASCO
Review and Impact of the NCDB PUF Moderator: Sandra Wong, MD, MS, FACS, FASCO Financial Disclosure I do not have personal financial relationships with any commercial interests Learning Objectives At the
More informationSurvival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery
ORIGINAL ARTICLE Survival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery Ann C. Raldow, BS,* Veronica L. Chiang, MD,w Jonathan P.
More informationDifference in the recurrence rate between right- and left-sided colon cancer: a 17-year experience at a single institution
Surg Today (2014) 44:1685 1691 DOI 10.1007/s00595-013-0748-5 ORIGINAL ARTICLE Difference in the recurrence rate between right- and left-sided colon cancer: a 17-year experience at a single institution
More informationThe role of cytoreductive. nephrectomy in elderly patients. with metastatic renal cell. carcinoma in an era of targeted. therapy
The role of cytoreductive nephrectomy in elderly patients with metastatic renal cell carcinoma in an era of targeted therapy Dipesh Uprety, MD Amir Bista, MD Yazhini Vallatharasu, MD Angela Smith, MA David
More informationCD133 Protein Expression as a Biomarker for Early Detection of Gastric Cancer.
CD133 Protein Expression as a Biomarker for Early Detection of Gastric Cancer. Sameer Al Diffalha, MD Domenico Coppola, MD February 3rd 2017 Introduction of Gastric Cancers (GC) 4th most common cancer
More informationDoctor, How Am I Doing? Conditional Survival Analyses
Doctor, How Am I Doing? Conditional Survival Analyses Background Survival rates usually reported from time of diagnosis only Doesn't reflect changing hazard rates over time: early: higher hazard rate late:
More informationORIGINAL ARTICLE. Predicting the Prognosis of Oral Squamous Cell Carcinoma After First Recurrence
ORIGINAL ARTICLE Predicting the Prognosis of Oral Squamous Cell Carcinoma After First Recurrence Michael D. Kernohan, FDSRCS, FRCS, MSc; Jonathan R. Clark, FRACS; Kan Gao, BEng; Ardalan Ebrahimi, FRACS;
More informationPrognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer
Prognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer Hee Jung Kwon, Nuri Jang, Min Hui Park, Young Kyung Bae Department of Pathology, Yeungnam
More informationClinicopathologic Characteristics and Prognosis of Gastric Cancer in Young Patients
Yonago Acta medica 2012;55:57 61 Clinicopathologic Characteristics and Prognosis of Gastric Cancer in Young Patients Hiroaki Saito, Seigo Takaya, Yoji Fukumoto, Tomohiro Osaki, Shigeru Tatebe and Masahide
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationStage III Colon Cancer Susquehanna Cancer Center Warren L Robinson, MD, FACP May 9, 2007
Stage III Colon Cancer Susquehanna Cancer Center 1997-21 Warren L Robinson, MD, FACP May 9, 27 Stage III Colon Cancer Susquehanna Cancer Center 1997-21 Colorectal cancer is the third most common cancer
More informationNeoadjuvant Therapy for Rectal Cancer is Overrated. Joon H. Lee, Research Resident University of Colorado 8/31/2009
Neoadjuvant Therapy for Rectal Cancer is Overrated Joon H. Lee, Research Resident University of Colorado 8/31/2009 Objectives Brief overview of staging rectal cancer Current guidelines for evaluation and
More informationColorectal Cancer and FDG PET/CT
Hybrid imaging in colorectal & esophageal cancer Emmanuel Deshayes IAEA WorkShop, November 2017 Colorectal Cancer and FDG PET/CT 1 Clinical background Cancer of the colon and rectum is one of the most
More informationAre there the specific prognostic factors for triplenegative subtype of early breast cancers (pt1-2n0m0)?
Are there the specific prognostic factors for triplenegative subtype of early breast cancers (pt1-2n0m0)? Department of General Surgery, Anam Hospital, Korea University, College of Medicine, 126-, Anam-dong
More informationColorectal cancer Chapelle, J Clin Oncol, 2010
Colorectal cancer Chapelle, J Clin Oncol, 2010 Early-Stage Colorectal cancer: Microsatellite instability, multigene assay & emerging molecular strategy Asit Paul, MD, PhD 11/24/15 Mr. X: A 50 yo asymptomatic
More informationIndeterminate Pulmonary Nodules in Patients with Colorectal Cancer
Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer Jai Sule 1, Kah Wai Cheong 2, Stella Bee 2, Bettina Lieske 2,3 1 Dept of Cardiothoracic and Vascular Surgery, University Surgical Cluster,
More informationPerigastric lymph node metastases in gastric cancer: comparison of different staging systems
Gastric Cancer (1999) 2: 201 205 Original article 1999 by International and Japanese Gastric Cancer Associations Perigastric lymph node metastases in gastric cancer: comparison of different staging systems
More informationPrognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China
www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,000 116,000 120M Open access books available International authors and editors Downloads Our
More informationHistologic Characteristics Enhance Predictive Value of American Joint Committee on Cancer Staging in Resectable Pancreas Cancer
Original Article Histologic Characteristics Enhance Predictive Value of American Joint Committee on Cancer Staging in Resectable Pancreas Cancer James Helm, MD, PhD 1,2,3,4,5 ; Barbara A. Centeno, MD 3,6,7
More informationCOLORECTAL CARCINOMA
QUICK REFERENCE FOR HEALTHCARE PROVIDERS MANAGEMENT OF COLORECTAL CARCINOMA Ministry of Health Malaysia Malaysian Society of Colorectal Surgeons Malaysian Society of Gastroenterology & Hepatology Malaysian
More informationSatisfactory surgical outcome of T2 gastric cancer after modified D2 lymphadenectomy
Original Article Satisfactory surgical outcome of T2 gastric cancer after modified D2 lymphadenectomy Shupeng Zhang 1, Liangliang Wu 2, Xiaona Wang 2, Xuewei Ding 2, Han Liang 2 1 Department of General
More informationTable S2. Expression of PRMT7 in clinical breast carcinoma samples
Table S2. Expression of PRMT7 in clinical breast carcinoma samples (All data were obtained from cancer microarray database Oncomine.) Analysis type* Analysis Class(number sampels) 1 2 3 4 Correlation (up/down)#
More informationMeta analysis in Rectal Cancer
Meta analysis in Rectal Cancer Dr. Monica Irukulla Professor and Head Department of Radiation Oncology Nizam s Institute of Medical Sciences hyderabad Areas of meta analysis in rectal cancers Epidemiology
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationLaparoscopic right-sided colon resection for colon cancer has the control group so far been chosen correctly?
Pelz et al. World Journal of Surgical Oncology (2018) 16:117 https://doi.org/10.1186/s12957-018-1417-3 RESEARCH Open Access Laparoscopic right-sided colon resection for colon cancer has the control group
More informationTitle: What is the role of pre-operative PET/PET-CT in the management of patients with
Title: What is the role of pre-operative PET/PET-CT in the management of patients with potentially resectable colorectal cancer liver metastasis? Pablo E. Serrano, Julian F. Daza, Natalie M. Solis June
More informationHigh expression of fibroblast activation protein is an adverse prognosticator in gastric cancer.
Biomedical Research 2017; 28 (18): 7779-7783 ISSN 0970-938X www.biomedres.info High expression of fibroblast activation protein is an adverse prognosticator in gastric cancer. Hu Song 1, Qi-yu Liu 2, Zhi-wei
More informationUpper urinary tract urothelial carcinomas (UTUC)
Prognostic Role of Lymphovascular Invasion in Patients with Urothelial Carcinoma of the Upper Urinary Tract Manel Mellouli 1 *, Slim Charfi 1, Walid Smaoui 2, Rim Kallel 1, Abdelmajid Khabir 1, Mehdi Bouacida
More informationImpact of esophageal cancer staging on overall survival and disease-free survival based on the 2010 AJCC classification by lymph nodes
Journal of Radiation Research, 2013, 54, 307 314 doi: 10.1093/jrr/rrs096 Advance Access Publication 2 November 2012 Impact of esophageal cancer staging on overall survival and disease-free survival based
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationPrognostic Impact of Hyperglycemia in Patients with Locally Advanced Squamous Cell Carcinoma of Cervix Receiving Definite Radiotherapy
Prognostic Impact of Hyperglycemia in Patients with Locally Advanced Squamous Cell Carcinoma of Cervix Receiving Definite Radiotherapy 2016.04.08 KCCH 김문홍 DM and prediabetes in cancer Negative impact on
More informationBackground: Patients and methods: Results: Conclusions:
Chapter 7 7 Results of European pooled analysis of IORT containing multimodality treatment for locally advanced rectal cancer: adjuvant chemotherapy prevents local recurrence rather than distant metastase
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationProviding Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationADJUVANT CHEMOTHERAPY FOR RECTAL CANCER
ESMO Preceptorship Programme Colorectal Cancer Barcelona November, 25-26, 2016 ADJUVANT CHEMOTHERAPY FOR RECTAL CANCER Andrés Cervantes Professor of Medicine OLD APPROACH TO RECTAL CANCER Surgical resection
More informationCitation for published version (APA): Bartels, S. A. L. (2013). Laparoscopic colorectal surgery: beyond the short-term effects
UvA-DARE (Digital Academic Repository) Laparoscopic colorectal surgery: beyond the short-term effects Bartels, S.A.L. Link to publication Citation for published version (APA): Bartels, S. A. L. (2013).
More informationVisceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size
GENERAL THORACIC Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size Elizabeth David, MD, Peter F. Thall, PhD, Neda Kalhor, MD, Wayne L. Hofstetter,
More informationPrognostic significance of metastatic lymph node ratio: the lymph node ratio could be a prognostic indicator for patients with gastric cancer
Hou et al. World Journal of Surgical Oncology (2018) 16:198 https://doi.org/10.1186/s12957-018-1504-5 REVIEW Open Access Prognostic significance of metastatic lymph node ratio: the lymph node ratio could
More informationWorkshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI
XXI CONGRESSO NAZIONALE AIRO Genova, 19-22 novembre 2011 Workshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI PIERA NAVARRIA Unità Operativa di Radioterapia e Radiochirurgia Humanitas Cancer
More information